Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

@article{Devriese2012EribulinMP,
  title={Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole},
  author={Lot A. Devriese and Marja Mergui-Roelvink and Jantien Wanders and AndrewM. Jenner and Geoff N Edwards and Larisa Reyderman and William Copalu and Fuping Peng and Serena Marchetti and Jos H. Beijnen and Jan H. M. Schellens},
  journal={Investigational New Drugs},
  year={2012},
  volume={31},
  pages={381-389}
}
Purpose To study the influence of repeated oral administration of ketoconazole, a potent CYP3A4 inhibitor, on the plasma pharmacokinetics of eribulin mesylate administered by single-dose intravenous infusion. Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that is currently under development in phase I-III trials for the treatment of solid tumors. Experimental design A randomized, open-label, two treatments, two sequences, crossover phase I study was performed in patients with… CONTINUE READING